Download PDF

1. Company Snapshot

1.a. Company Description

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia.


Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Show Full description

1.b. Last Insights on PODD

Insulet Corporation's recent performance was negatively impacted by several factors. Several institutional investors, including Fisher Asset Management LLC, Brown Advisory Inc., and Central Pacific Bank Trust Division, reduced their stakes in the company, with Central Pacific Bank Trust Division decreasing its holdings by 99.8%. Conversely, some investors increased their positions, such as Asset Management One Co. Ltd., which raised its stake by 29.0%. Insulet's growth prospects remain intact, with the company poised to benefit from its diabetes-focused business. Recently, the company reported better-than-expected Q4 earnings.

1.c. Company Highlights

2. Insulet Corporation Delivers Strong Q4 and Full-Year 2025 Results

Insulet Corporation reported a robust fourth quarter and full-year 2025 results, with total company revenues reaching $784 million, a 29% constant currency growth. The strong performance enabled the company to surpass $2.7 billion in revenue for the full year, more than doubling its revenue base over the last three years. The company's gross margin expanded 180 basis points to 73.6%, and operating margin expanded 270 basis points to 17.5%. Earnings per share (EPS) for the year was $1.44, slightly below estimates of $1.48.

Publication Date: Feb -19

📋 Highlights
  • Revenue Surge: Q4 revenue reached $784M (+29% YoY constant currency), with FY2025 total revenue exceeding $2.7B (+30% YoY constant currency).
  • Margin Expansion: Gross margin expanded 180 bps to 73.6%, and operating margin grew 270 bps to 17.6% in FY2025.
  • New Customer Growth: Record global new customer starts in FY2025, with 85% in the U.S. transitioning from multiple daily injections.
  • International Acceleration: International revenue surged 41.7% constant currency in Q4, driven by volume and pricing, with a $10B+ untapped type 1 market globally.
  • 2026 Guidance: Projects 21-23% Omnipod revenue growth and 20-22% total revenue growth, with adjusted EPS rising >25% and free cash flow stability.

Revenue Growth Drivers

The company's revenue growth was driven by strong demand for Omnipod 5 across type 1 and type 2 customers, with U.S. Omnipod revenue growing 28% in the fourth quarter and 27.2% for the year. International Omnipod revenue grew 50.7% on a reported basis and 41.7% on a constant currency basis for the fourth quarter. According to Ashley McEvoy, "We achieved record new customer starts across both the U.S. and international in the fourth quarter and for the full year, with the vast majority coming from people transitioning from multiple daily injections."

Guidance and Outlook

The company provided guidance for 2026, expecting Omnipod revenue to grow 21% to 23% and total company revenue to grow 20% to 22%. Adjusted EPS is expected to increase by more than 25%. The guidance reflects a balanced view of the outlook, and the company is confident in its ability to deliver the guidance. Analysts estimate next year's revenue growth at 19.0%, indicating a slight conservatism in the company's guidance.

Valuation Metrics

To understand what's priced in, we can look at Insulet Corporation's valuation metrics. The company's Price-to-Sales (P/S) Ratio is 6.7, and the EV/EBITDA ratio is 38.28. The ROE is 17.36%, indicating a strong return on equity. The Net Debt/EBITDA ratio is -1.53, indicating a net cash position. These metrics suggest that the company's strong growth prospects are reflected in its valuation.

3. NewsRoom

Card image cap

Insulet to Present EVOLUTION 2 Results on Omnipod® Fully Closed-Loop System for Adults with Type 2 Diabetes at International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Mar -10

Source: businesswire.com

Card image cap

Blair William & Co. IL Sells 20,182 Shares of Insulet Corporation $PODD

Mar -08

Source: defenseworld.net

Card image cap

DNB Asset Management AS Raises Stake in Insulet Corporation $PODD

Mar -01

Source: defenseworld.net

Card image cap

Head-To-Head Comparison: Insulet (NASDAQ:PODD) vs. United Health Products (OTCMKTS:UEEC)

Mar -01

Source: defenseworld.net

Card image cap

Insulet Corporation $PODD Shares Bought by Aster Capital Management DIFC Ltd

Feb -27

Source: defenseworld.net

Card image cap

Andra AP fonden Buys 28,800 Shares of Insulet Corporation $PODD

Feb -27

Source: defenseworld.net

Card image cap

Insulet: The Growth Doesn't Stop Here

Feb -27

Source: seekingalpha.com

Card image cap

Fox Run Management L.L.C. Buys 4,813 Shares of Insulet Corporation $PODD

Feb -25

Source: defenseworld.net

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (13.72%)

6. Segments

United States Omnipod

Expected Growth: 13.5%

Insulet's Omnipod growth is driven by increasing adoption of tubeless insulin delivery systems, expanding reimbursement coverage, and growing awareness of the benefits of continuous glucose monitoring. Additionally, the company's strategic partnerships, investments in digital health technologies, and geographic expansion into new markets are contributing to the 13.5% growth rate.

International Omnipod

Expected Growth: 14.5%

Insulet's International Omnipod growth is driven by increasing adoption of tubeless insulin delivery systems, expanding global presence, and growing demand for diabetes management solutions. Strong marketing efforts, strategic partnerships, and favorable reimbursement trends also contribute to the 14.5% growth rate.

Drug Delivery

Expected Growth: 12.5%

Insulet Corporation's 12.5% growth in Drug Delivery is driven by increasing adoption of Omnipod insulin management systems, expansion into new markets, and growing demand for tubeless and wireless insulin delivery solutions. Additionally, strategic partnerships and investments in research and development are contributing to the company's growth momentum.

7. Detailed Products

Omnipod Insulin Management System

A wearable, tubeless insulin pump that provides continuous insulin delivery and insulin bolus dosing for people with diabetes.

Omnipod DASH System

A next-generation insulin management system that combines a wearable insulin pump with a mobile app and a Contour Next Link 2.4 meter.

Omnipod 5 System

An automated insulin delivery system that integrates with a continuous glucose monitor and a mobile app to provide personalized insulin dosing recommendations.

8. Insulet Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

Insulet Corporation's Omnipod System is a unique product with limited substitutes, but patients may opt for traditional insulin pumps or multiple daily injections as alternatives.

Bargaining Power Of Customers

Insulet Corporation's customers, primarily patients with diabetes, have limited bargaining power due to the unique nature of the Omnipod System and the company's strong brand reputation.

Bargaining Power Of Suppliers

Insulet Corporation has a diversified supplier base, reducing dependence on individual suppliers and limiting their bargaining power.

Threat Of New Entrants

The medical device industry, particularly the insulin pump market, has high barriers to entry, including regulatory hurdles and significant R&D investments, making it challenging for new entrants to compete with Insulet Corporation.

Intensity Of Rivalry

The insulin pump market is moderately competitive, with a few established players, including Medtronic and Tandem Diabetes Care, but Insulet Corporation's unique product offerings and strong brand reputation help to differentiate it from competitors.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 65.95%
Debt Cost 3.95%
Equity Weight 34.05%
Equity Cost 8.88%
WACC 5.63%
Leverage 193.71%

11. Quality Control: Insulet Corporation passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Insulet

A-Score: 5.3/10

Value: 0.2

Growth: 9.6

Quality: 7.9

Yield: 0.0

Momentum: 8.5

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
CONMED

A-Score: 4.8/10

Value: 7.4

Growth: 6.4

Quality: 5.9

Yield: 3.0

Momentum: 1.0

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
Inari Medical

A-Score: 4.8/10

Value: 4.0

Growth: 8.0

Quality: 4.8

Yield: 0.0

Momentum: 9.5

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
iRhythm Technologies

A-Score: 4.7/10

Value: 4.2

Growth: 6.1

Quality: 3.2

Yield: 0.0

Momentum: 10.0

Volatility: 4.7

1-Year Total Return ->

View Full Report
Stock-Card
Bio-Rad

A-Score: 4.0/10

Value: 6.5

Growth: 2.3

Quality: 4.7

Yield: 0.0

Momentum: 5.0

Volatility: 5.3

1-Year Total Return ->

View Full Report
Stock-Card
Integra LifeSciences

A-Score: 3.0/10

Value: 8.3

Growth: 2.3

Quality: 4.1

Yield: 0.0

Momentum: 0.5

Volatility: 3.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

238.24$

Current Price

238.24$

Potential

-0.00%

Expected Cash-Flows